Context: Familial glucocorticoid deficiency (FGD) is an autosomal recessive disorder characterized by distinct clinical, biochemical, and genetic abnormalities. The prevalence of FGD is unknown, with the likelihood that cases remain undiagnosed. We noted a significant proportion of our FGD cases are Irish Travelers. Irish Travelers are an endogamous nomadic group ethnically and genetically distinct from Roma gypsies.
F
amilial glucocorticoid deficiency (FGD) was first described by Sheperd and Mason in 1959 (1) and is characterized by clinical, biochemical, and genetic abnormalities (2) (3) (4) (5) (6) (7) (8) (9) . It is composed of three types; FGD type 1 (OMIM 202200) a defect in the ACTH [melanocortin-2 receptor (MC2-R)] receptor gene; FGD type 2 mutations in MC2-R accessory protein (MRAP; OMIM 609196), a protein required for trafficking the MC2R to the cell surface (10) ; and FGD type 3, a term used to define patients with no identifiable mutations in either gene, although some FGD3 patients have had disease mapped to a locus on chromosome 8q (11) .
Patients and Methods
Specialist endocrine departments in the Republic of Ireland were contacted to identify FGD patients. The National Centre for Medical Genetics database was searched. Patients with FGD were identified based on clinical features, high ACTH, low cortisol, and normal renin and aldosterone concentrations consistent with isolated glucocorticoid defi-ciency. A detailed chart review was compiled, and MC2R and MRAP sequencing undertaken on all patients. Ethics was approved by The Our Lady's Children's Hospital Crumlin Ethics board.
Prevalence
As part of a larger study examining the prevalence of ACTH resistance in Ireland, we estimated prevalence figures for FGD among a genetic isolated community, the Irish Travelers. We used the Republic of Ireland Census of 2006 to provide up-to-date data for estimation of the denominator (12) . The total population in the Republic of Ireland at this time was 4,239,848 (12) . We identified 21 cases of FGD, generating an overall prevalence of one in 201,898. Another child with FGD type 1 died before this study. All cases were Caucasian, except one child of Sudanese origin.
There were nine cases of FGD among a total population of 22,557 Irish Travelers, yielding a disease prevalence of one in 2,506 and a carrier frequency of one in 25. Subdividing further into the age range of presentation, there are 5989 Irish Travelers aged between 4 and 15 yr, generating a disease prevalence in this age range of one in 665.
Presentation
Eight of the nine cases presented over the age of 4 yr with mild dysmorphic features and short stature. In the three kindreds from the same Irish Traveler nomadic group, all children presented late and were relatively asymptomatic. Measurement of cortisol and ACTH had been performed at a mean age of 1.0 yr (range 3 months to 2.5 yr) for screening purposes in a high-risk population and was normal in all but one case (Table 1) . Others were screened because of unexplained infant death within the family or a family history of adrenal disease. The majority of these nine children presented with acute childhood illness to a local hospital. Initial clinical symptoms included hypoglycemia in six of nine (67%); failure to thrive in seven of nine (78%); and hyperpigmentation in eight of nine (90%).
The mean birth weight was 2.5 kg (range 1.6 -3.4 kg) in the Irish Traveler children. Six of nine (67%) were small for gestational age (SGA). Two 2 of nine (23%) were also preterm at 34 wk gestation with a birth weight Ϫ2.0 SD score (SDS) and Ϫ2.35 SDS, respectively (18) . This tendency to SGA is to our knowledge unreported in the description of FGD and may account for the short stature in this cohort at time of presentation.
Later biochemical analysis at a mean age of 5.3 yr (range 4.4 -8.5 yr) was abnormal and typical of classic FGD. All cases were commenced on hydrocortisone replacement therapy at a median dose 12.8 mg/m 2 ⅐d (range 10 -15 mg/m 2 ⅐d) and remain on replacement therapy. ACTH concentrations remained high despite standard glucocorticoid replacement therapy in all nine cases.
One child had screened positive (using mitomycin C) for a diagnosis of mosaic Fanconi anemia. Fanconi anemia is common among Irish Travelers and a common homozygous deletion of exons 11-14 in the FANCA gene has been identified (13) . However, he tested negative for this mutation and has not developed the typical hematological signs of the condition at age 10 yr, nor has he the typical malformations, suggesting alternative mechanisms of chromosomal breakage. Low normal natural killer (NK) cells were observed in three cases but all were well. The other patients had normal NK levels and their growth parameters were not dissimilar. Excess endogenous glucocorticoids affect spontaneous NK cell activity, and exogenous administration may have the same effect; (14) ; however, none of the Irish Traveler children were on excess glucocorticoid therapy.
Non-MC2R/MRAP mutations in Irish Traveler children
The nine affected children come from three separate clans. Extensive pedigree analysis has not yet revealed a common ancestor. However, affected individuals from all three clans had normal MC2R and MRAP sequencing, and it is likely that they have a common mutation in an as-yet-unidentified gene. Other causes of adrenal insufficiency, adrenoleukodystrophy, congenital adrenal hyperplasia, AAA syndrome (Alarcrima, Achalasia, and Adrenal insufficiency), and Addison's disease were excluded.
Phenotype and growth
There were some minor dysmorphic facial features common to all nine cases in the Irish Traveler group including a thin upper lip, cupids bow lip, prominence of the forehead, and mild (Fig. 1) or severe hyperpigmentation [eight of nine (90%)]. This evolved into a picture of latepresenting adrenal insufficiency with subsequent short stature on standard replacement hydrocortisone doses (10 -15 mg/m 2 ⅐d). Six cases were short at presentation and some had a history of failure to thrive (Table 1 ). The current heights are Ϫ1 to Ϫ2 SD below the expected midparental height. This was on standard replacement hydrocortisone doses (10 -15 mg/m 2 ⅐d). Most growth profiles slowed down after glucocorticoid replacement therapy started, and some continued to grow poorly, irrespective of target centiles. Many cases had their hydrocortisone reduced to less than standard glucocorticoid replacement therapy to exclude any growth-inhibiting effect. One patient had daily hydrocortisone withdrawn for 5 months, with no catch-up growth documented.
Discussion
This data set demonstrates the prevalence of FGD in the Republic of Ireland population of one in 201,900, with a carrier frequency of FGD of one in 449 for the 2006 Republic of Ireland Census population (12) . We report an age-related (4 -15 yr) prevalence for FGD of one in 665 among Irish Travelers with a carrier frequency of one in 13. This is the highest recorded prevalence for FGD quoted worldwide. The figures quoted are minimum prevalence figures and are probably an underestimate because the phenotype is subtle and cases are likely to be missed in adulthood. These cases may have died before diagnosis, never presented to medical attention, or simply have been diagnosed with Addison's disease in the adult population.
Irish Travelers are an endogamous nomadic group. There are 22,557 Irish Travelers in the Republic of Ireland (12) . Another 1710 Irish Travelers live in Northern Ireland (15) , and it is estimated that there are approximately 5000 on the mainland United Kingdom, with a similar number residing in mainland Europe (15) . More than 59 autosomal recessive conditions are known in this community including 19 inborn errors of metabolism (16) . A recent paper reported 23% of Irish Travelers marry first cousins (17) . Second-cousin marriage would also be very common, although there are no recent figures available. Anecdotally the majority of Irish Travelers marry within their family with only a small percentage marrying outside the community. These nine FGD children came from three separate clans within the Irish Traveler community. Despite drawing a detailed threegeneration pedigree analysis, we were unable to link the three families. All these children were from first cousin marriages.
Most descriptions of FGD highlight early-onset presentation (Ͻ5 yr), often with tall stature; however, in the patients from the IT group, six of nine (67%) were SGA and remained small at presentation. Ninety percent (eight of nine) presented late and showed significant hyperpigmentation. All cases had been tested (intercurrent illness or family screen) initially and were normal at a mean of 1.0 yr (range 3 months to 2.5 yr) before eventual clinical presentation. The fact that initial biochemical testing was normal in all cases (Table 1 ) delayed the diagnosis of FGD. This emphasizes the need to revisit the possibility of the diagnosis of FGD in the absence, at present, of a definitive genetic test(s). Although the biochemistry appeared normal initially, later biochemical analysis was typical of cases presenting with FGD types 1 or 2. The slowly evolving FGD in the IT group may imply a degenerative process of the adrenal cortex. This has been described in isolated cases in MC2R, with one child presenting as late as 9 yr old (Clark, A. J., personal communication). However, all cases in this series are normal for the MC2R mutation on sequencing analysis.
All cases were commenced on hydrocortisone replacement therapy at a median dose 12.8 mg/m 2 ⅐d and remained on replacement therapy for a median age 5.3 yr (range 4.1-8.5 yr). Despite standard replacement therapy, the final height was below expectation in contrast to type 1 FGD patients, who have a mean height above normal. The heights in children with MRAP (FGD2) have not been reported. All nine of our IT patients fell below expected midparental height and six of nine (67%) were Ϫ1.1 to Ϫ2.0 SDS below mean height. Whether this suggests an enhanced sensitivity to glucocorticoids, a statural abnormality associated with FGD in this population, or another growth-restricting abnormality in this inbred population remains unclear at present.
It has been suggested that height velocity is faster in the absence of normal endogenous glucocorticoid and slows with the introduction of replacement therapy. This was considered in all nine patients with poor height velocity and poor final height, who were tried on low glucocorticoid replacement doses with none greater than 15 mg/m 2 ⅐d.
Conclusions
We describe the prevalence of a new variant of FGD in the Irish Traveler subpopulation. The variant condition differs from that seen in patients with types 1 and 2 FGD with later presentation but SGA at birth and normal initial biochemistry. We have also estimated minimum prevalence figures for FGD among the general population in the Republic of Ireland. We recommend considering a diagnosis of FGD in children from this community who present with SGA, hypoglycemia, and hyperpigmentation. In those with a family history of FGD, until the genetic mutation is identified, we recommend clinical follow-up with instructions for the family to seek medical advice during intercurrent illness. We await final gene mapping to locate the gene locus specific to FGD in the Irish Traveling community (16) .
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